Back
14
Day Range
$5.01
$5.19
52-Week Range
$4.25
$8.69
Volume
1,706,850
50D / 200D Avg
$5.98
/
$6.45
Prev Close
$5.01
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 12.2 | 0.4 |
| P/B | — | 2.9 |
| ROE % | — | 3.7 |
| Net Margin % | 1.5 | 3.9 |
| Rev Growth 5Y % | 5.2 | 10.0 |
| D/E | — | 0.2 |
Analyst Price Target
Hold
$8.00
+56.9%
Forward P/E
1.2
Forward EPS
$4.36
EPS Growth (est.)
+0.0%
Est. Revenue
11 B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$3.59
$3.57 – $3.62
|
9.7 B | 1 |
| FY2029 |
$3.33
$3.31 – $3.35
|
9.7 B | 1 |
| FY2028 |
$3.08
$3.07 – $3.10
|
9.8 B | 2 |
Key Takeaways
Revenue grew 5.15% annually over 5 years — modest growth
Generating 1.00B in free cash flow
P/E of 12.17 — trading at a low valuation
Cash machine — converts 645.94% of earnings into free cash flow
Capital efficient — spends only 3.85% of revenue on capex
Interest coverage of 1.37× — tight debt servicing
Growth
Revenue Growth (5Y)
5.15%
Revenue (1Y)7.11%
Earnings (1Y)N/A
FCF Growth (3Y)14.88%
Quality
Return on Equity
N/A
ROIC7.51%
Net Margin1.51%
Op. Margin20.07%
Safety
Debt / Equity
N/A
Current Ratio1.47
Interest Coverage1.37
Valuation
P/E Ratio
12.17
P/B RatioN/A
EV/EBITDA10.52
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7.11% | Revenue Growth (3Y) | 8.50% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 5.15% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 10.31B | Net Income (TTM) | 155.28M |
| ROE | N/A | ROA | 0.59% |
| Gross Margin | 68.33% | Operating Margin | 20.07% |
| Net Margin | 1.51% | Free Cash Flow (TTM) | 1.00B |
| ROIC | 7.51% | FCF Growth (3Y) | 14.88% |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1.47 |
| Interest Coverage | 1.37 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 12.17 | P/B Ratio | N/A |
| P/S Ratio | 0.18 | PEG Ratio | -0.04 |
| EV/EBITDA | 10.52 | Dividend Yield | 0.00% |
| Market Cap | 1.89B | Enterprise Value | 21.77B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10.31B | 9.63B | 8.76B | 8.12B | 8.43B |
| Net Income | 155.28M | -46.00M | -592.00M | -225.00M | -948.00M |
| EPS (Diluted) | 0.41 | -0.13 | -1.62 | -0.62 | -2.61 |
| Gross Profit | 7.04B | 6.84B | 6.20B | 5.76B | 6.04B |
| Operating Income | 2.07B | 1.55B | 963.00M | 454.00M | 450.00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 26.32B | 26.52B | 27.35B | 25.69B | 29.20B |
| Total Liabilities | 25.94B | 26.85B | 27.43B | 25.43B | 29.24B |
| Shareholders' Equity | -552.99M | -1.28B | -1.02B | -692.00M | -106.00M |
| Total Debt | 21.21B | 21.83B | 22.39B | 20.77B | 22.65B |
| Cash & Equivalents | 1.32B | 1.18B | 947.00M | 564.00M | 582.00M |
| Current Assets | 6.15B | 5.77B | 5.60B | 4.25B | 5.61B |
| Current Liabilities | 4.17B | 6.75B | 4.30B | 3.94B | 5.20B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#506 of 616
Recent Activity
Entered
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026